MIRA Pharmaceuticals, Inc. Restricted Investments, at Fair Value
MIRA Pharmaceuticals, Inc. (MIRA) had Restricted Investments, at Fair Value of $86.00 thousand as of 2026-03-29, per its 10-Q filed 2026-08-12.
Financial Statements › Notes
us-gaap:RestrictedInvestmentsAtFairValue · last filed 2026-08-12
- 2026-03-29: Restricted Investments, at Fair Value $86.00K.
- 2025-12-16: Restricted Investments, at Fair Value $90.63K.
- 2025-07-18: Restricted Investments, at Fair Value $93.75K.
| Period end | Restricted Investments, at Fair Value |
|---|---|
| 2026-03-29 | $86.00K 10-Q · filed 2026-08-12 |
| 2025-12-16 | $90.63K 10-K · filed 2026-03-31 |
| 2025-07-18 | $93.75K 10-K · filed 2026-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B |